What is Fatty Liver Disease?

Fatty liver disease means excess fat has accumulated in liver cells. The most common form is now called metabolic dysfunction-associated steatotic liver disease (MASLD), which occurs alongside features such as excess weight, high blood glucose, high blood pressure, or abnormal lipids. It usually causes no symptoms, and the key question is how much scarring (fibrosis) is present.

Key takeaways

  • MASLD is the most common liver condition worldwide and is usually found incidentally on blood tests or imaging.
  • The naming changed in 2023: NAFLD became MASLD, and NASH became MASH, tying the diagnosis to metabolic risk factors.
  • Fibrosis stage, not fat content, is what predicts long-term liver outcomes.
  • Non-invasive scores such as FIB-4 and elastography have largely replaced routine biopsy for risk assessment.
  • Sustained weight loss of 7-10% can substantially reduce liver fat and inflammation.

Overview

Fat accumulates in liver cells when the liver receives or produces more fat than it can export or burn. In its early stage — simple steatosis — this causes no symptoms and does relatively little harm. In a subset of people the fat is accompanied by inflammation and liver cell injury, a stage now called metabolic dysfunction-associated steatohepatitis (MASH), and that inflammation can drive progressive scarring. Over years, scarring can advance to cirrhosis with its associated risks of liver failure and liver cancer.

What makes this condition important is its scale and its silence. A large share of adults with obesity or type 2 diabetes have MASLD, and most do not know. It is usually discovered when liver enzymes come back mildly abnormal or when an ultrasound done for another reason shows a bright liver. It is also a cardiovascular condition in disguise: people with MASLD are more likely to die of heart disease than of liver disease, so the assessment should always look beyond the liver.

What Fatty Liver Disease is

The terminology was revised in 2023. Steatotic liver disease is the umbrella term. MASLD requires hepatic steatosis plus at least one cardiometabolic criterion such as overweight or increased waist circumference, raised fasting glucose or diabetes, high blood pressure, high triglycerides, or low HDL cholesterol. MetALD describes people who meet MASLD criteria and also drink at levels that likely contribute, while alcohol-related liver disease is a separate category.

Within MASLD, the important distinction is between simple fat accumulation and steatohepatitis (MASH), where inflammation and ballooning of liver cells occur. Fibrosis is then staged from F0 (none) to F4 (cirrhosis). Fibrosis stage is what correlates with long-term liver and overall mortality, which is why assessment focuses on it rather than on how much fat is visible.

Common symptoms

MASLD is usually silent; symptoms, when they appear, tend to signal advanced disease.

  • No symptoms — the usual presentation
  • Fatigue that is difficult to attribute to anything specific
  • Vague discomfort or fullness in the upper right abdomen
  • Mildly abnormal liver enzymes found on routine blood tests
  • An unexpectedly bright or fatty-appearing liver on an ultrasound done for another reason

Less common symptoms

  • Yellowing of the skin or eyes (jaundice) — a sign of advanced liver disease
  • Swelling of the legs or abdominal distension from fluid (ascites)
  • Easy bruising or bleeding
  • Confusion or disturbed sleep-wake cycle (hepatic encephalopathy)
  • Itching without a rash

Risk factors

  • Type 2 diabetes and insulin resistance — the strongest associations, present in a large share of cases
  • Obesity, particularly central adiposity — but MASLD also occurs at normal BMI
  • High triglycerides and low HDL cholesterol — part of the same metabolic cluster
  • High blood pressure — one of the defining cardiometabolic criteria
  • Polycystic ovary syndrome — associated with insulin resistance and liver fat
  • Obstructive sleep apnea — independently associated with progression
  • Rapid weight gain or a diet high in fructose-sweetened beverages
  • Certain genetic variants such as PNPLA3, which raise risk and progression independent of weight
  • Hypothyroidism and some medications, including corticosteroids, tamoxifen, and amiodarone

Causes

The core problem is insulin resistance. When muscle and fat tissue resist insulin, fatty acids are released into the circulation and delivered to the liver, while the liver simultaneously increases its own fat production — a process amplified by diets high in refined carbohydrate and fructose. If export as VLDL and oxidation cannot keep pace, fat accumulates inside liver cells.

Whether that progresses to inflammation and scarring depends on additional factors: genetic variants, oxidative stress, gut microbiome changes, and immune activation. This is why two people with similar liver fat can have completely different outcomes, and why risk assessment focuses on fibrosis rather than fat.

How it is diagnosed

Assessment answers two questions: is fat present, and how much scarring has developed?

Test or assessmentWhat it looks at
Liver enzymes (ALT and AST)Often mildly raised, but normal enzymes do not exclude MASLD or even advanced fibrosis. They are a starting point rather than a screening test.
Abdominal ultrasoundThe usual first imaging test; it detects moderate to severe fat accumulation but is insensitive to mild steatosis and cannot stage fibrosis.
FIB-4 scoreA simple calculation from age, AST, ALT, and platelet count used as a first-line fibrosis risk filter. A low score reliably rules out advanced fibrosis.
Transient elastography (FibroScan) or MR elastographyMeasures liver stiffness as a proxy for fibrosis, and controlled attenuation parameter for fat content. Widely used to avoid biopsy.
Tests to exclude other liver diseaseViral hepatitis serology, autoimmune markers, iron studies, and ceruloplasmin where relevant, plus an honest alcohol history.
Liver biopsyStill the reference standard for distinguishing MASH from simple steatosis, but now reserved for uncertain cases or trial participation.

Treatment overview

Treatment centres on the metabolic drivers, with liver-directed medication now available for selected people with MASH and fibrosis. The categories below describe approaches; suitability and dosing are decided by a clinician.

Weight reduction

The best-established intervention. Around 5% loss reduces liver fat, 7-10% improves inflammation, and greater sustained loss can reduce fibrosis in some people.

Dietary pattern change

Mediterranean-style eating with reduced refined carbohydrate and sugar-sweetened beverages has the strongest supporting evidence, independent of weight change.

Physical activity

Both aerobic and resistance exercise reduce liver fat even without weight loss, which makes activity worthwhile regardless of what the scale shows.

Alcohol reduction

Minimising or avoiding alcohol matters, since it compounds liver injury and shifts the diagnosis toward MetALD or alcohol-related disease.

Managing metabolic conditions

Treating type 2 diabetes, dyslipidemia, and hypertension. Certain diabetes and weight medication classes, including GLP-1 receptor agonists, have shown liver benefit in trials.

Liver-directed pharmacotherapy

A thyroid hormone receptor-beta agonist is now approved in the US for MASH with moderate to advanced fibrosis, prescribed by specialists with monitoring.

Metabolic surgery

For eligible people with obesity, bariatric surgery produces substantial and durable improvement in liver fat, inflammation, and often fibrosis.

Lifestyle considerations

  • Target gradual, sustained weight loss rather than rapid dieting; very rapid loss can transiently worsen liver inflammation.
  • Cut sugar-sweetened drinks entirely — fructose is handled almost exclusively by the liver.
  • Adopt a Mediterranean-style pattern: olive oil, fish, nuts, legumes, vegetables, and whole grains.
  • Get at least 150 minutes a week of moderate activity plus resistance training twice weekly.
  • Minimise alcohol, and avoid it entirely if fibrosis is present.
  • Have blood pressure, lipids, and glucose checked regularly — cardiovascular disease is the leading cause of death in MASLD.
  • Check with your clinician or pharmacist before starting supplements marketed for liver health; some cause liver injury.
  • Ask about hepatitis A and B vaccination if you are not already protected.

Prevention

  • Maintain a healthy weight and waist circumference through adulthood.
  • Limit sugar-sweetened beverages and refined carbohydrate.
  • Stay physically active most days.
  • Manage prediabetes and type 2 diabetes actively.
  • Keep alcohol within low-risk limits or avoid it.
  • Ask for fibrosis risk assessment such as a FIB-4 score if you have type 2 diabetes or obesity, since guidelines increasingly recommend it.

Warning signs and when to get help

Signs that need emergency care

If you believe you are experiencing a medical emergency, call emergency services immediately (911 in the United States).

  • Vomiting blood or passing black tarry stools — possible bleeding from varices in advanced liver disease
  • New confusion, disorientation, or marked drowsiness
  • Rapidly increasing abdominal swelling with fever and abdominal pain
  • Yellowing of the skin or eyes appearing suddenly

Signs that warrant a prompt appointment

These are not emergencies, but they are worth a call to your clinician rather than a wait-and-see.

  • Persistent fatigue with abnormal liver blood tests
  • New leg swelling or abdominal distension
  • Easy bruising or prolonged bleeding from small cuts
  • Persistent itching without a rash
  • Unintentional weight loss

Questions to ask a healthcare professional

Take these to your next appointment — or build an agenda with the Appointment Prep tool.

  • Do I have simple fatty liver or is there inflammation and scarring?
  • What is my FIB-4 score, and do I need elastography?
  • Have other causes of liver disease been excluded?
  • What weight loss target would make a meaningful difference for my liver?
  • How much alcohol, if any, is acceptable in my situation?
  • Should any of my current medicines be changed because of my liver?
  • Am I a candidate for liver-directed medication or a clinical trial?
  • How often should my liver and my cardiovascular risk be reassessed?

Frequently asked questions

What is the difference between NAFLD and MASLD?

They describe the same disease. In 2023 the naming changed from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease, which defines the condition by the metabolic features that cause it rather than by what it is not. NASH correspondingly became MASH.

Can fatty liver be reversed?

Liver fat can be substantially reduced and often cleared with sustained weight loss, dietary change, and exercise, and inflammation frequently improves too. Established cirrhosis is not reversible, which is why fibrosis assessment and early action matter.

Are my normal liver enzymes reassuring?

Only partly. Many people with MASLD, including some with advanced fibrosis, have normal ALT and AST. That is why non-invasive fibrosis scores such as FIB-4 and elastography are used rather than relying on enzymes alone.

Do liver detox supplements help?

There is no good evidence that detox products, cleanses, or most liver supplements improve fatty liver, and some herbal products have caused serious liver injury. Weight loss, dietary pattern, activity, and alcohol reduction are what have evidence behind them.

Can I have fatty liver at a normal weight?

Yes. Lean MASLD is well recognised, particularly in people with insulin resistance, certain genetic variants such as PNPLA3, or high intake of sugar-sweetened drinks. Body weight is one risk factor among several rather than a requirement.

Sources

Health Captain links to primary public-health and clinical sources so you can read the original material yourself. See our sources policy.

Medical disclaimerHealth Captain provides general educational information and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding questions about your health, symptoms, medications, or treatment.